Abstracts tagged "Glucosamine"

Abstract Number: 1190 • 2017 ACR/ARHP Annual Meeting
Orosomucoid 2 Serves As Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine Hydrochloride
Valentina Calamia¹, M Camacho¹, Ignacio Rego-Pérez¹, L González¹, P Fernández-Puente¹, F Picchi¹, Marta Herrero², Helena Martinez², C Ruiz-Romero¹ and Francisco J Blanco^3,4, ¹Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain, ²Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, ³RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, A Coruña, Spain, A Coruña, Spain, ⁴Rheumatology Division, ProteoRed/ISCIII, Proteomics Group, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Orosomucoid 2 Serves as Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine HydrochlorideV. Calamia, M. Camacho, I. Rego-PŽrez, L. Gonz‡lez, P. Fern‡ndez-Puente,…
Abstract Number: 1203 • 2017 ACR/ARHP Annual Meeting
Differences in Serum Protein Biomarkers between Combined Glucosamine and Chondroitin Versus Celecoxib Treatment in a Randomized, Double-Blind Trial in Osteoarthritis Patients
Sandi L Navarro¹, Marta Herrero², Helena Martinez², Jon Ladd¹, Yuzheng Zhang¹, Edward Lo¹, David Shelley¹, Timothy W Randolph¹, Yvonne Schwarz¹, Johanna W Lampe¹ and Paul D Lampe¹, ¹Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, ²Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain
Background/Purpose: Non-steroidal anti-inflammatory drugs, e.g., celecoxib, are commonly used for inflammatory conditions, including osteoarthritis (OA), but are associated with adverse effects. Combined glucosamine hydrochloride plus…
Abstract Number: 2145 • 2013 ACR/ARHP Annual Meeting
Impact On Cartilage Volume Changes Over Time Of Conventional Treatment and Of Glucosamine and Chondroitin Sulfate In Knee Osteoarthritis Patients: Data From The Osteoarthritis Initiative Cohort
Johanne Martel-Pelletier¹, Camille Roubille¹, Jean-Pierre Raynauld¹, François Abram², Pierre Dodin³, Marc Dorais⁴, Philippe Delorme¹ and Jean-Pierre Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ³Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ⁴StatSciences Inc., Notre-Dame de l’Île Perrot, QC, Canada
Background/Purpose: To explore, using data from participants enrolled in the progression cohort of the Osteoarthritis Initiative (OAI), the effects of conventional knee osteoarthritis (OA) pharmacological…
Abstract Number: 2471 • 2012 ACR/ARHP Annual Meeting
Oral Glucosamine Sulphate for the Prevention of Knee Osteoarthritis in Overweight Females; The First Ever Preventive Randomized Controlled Trial
Jos Runhaar¹, Marienke van Middelkoop¹, Max Reijman², Edwin Oei³, Dammis Vroegindeweij⁴, Gerjo van Osch², Bart Koes¹ and Sita Bierma-Zeinstra⁵, ¹General Practice, Erasmus MC, Rotterdam, Netherlands, ²Orthopaedics, Erasmus MC, Rotterdam, Netherlands, ³Radiology, Erasmus MC, Rotterdam, Netherlands, ⁴Radiology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Orthopaedics and General Practice, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Previous studies showed the largest effects of glucosamine on osteoarthritis (OA) symptoms of the knee joint and when used in an early phase of…
Abstract Number: 1135 • 2012 ACR/ARHP Annual Meeting
Combined Glucosamine and Chondroitin Sulfate, Once of Three Times Daily, Provide Clinically Relevant Analgesia in Knee Osteoarthritis
Jose R. Provenza¹, Samuel K. Shinjo², Joyce M. Silva³, Carla RGS. Peron⁴ and Francisco AC Rocha⁵, ¹Rheumatology, Pontifícia Universidade Católica de Campinas, Campinas, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Clinical Research, Sao Paulo, Brazil, ⁴Clinical Research, Laboratórios Aché Ltda, Sao Paulo, Brazil, ⁵Rheumatology, Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: The analgesic efficacy of combined glucosamine and chondroitin sulfate (CS) in knee osteoarthritis (OA) remains controversial. Criticism to previous studies includes small sample size,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].